On the same day it announced a $55 million E round, California biotech Versartis filed to go public in an $80 million IPO, planning to use its fast-growing bank account to get a promising orphan therapy through late-stage trials.

…read more

Source: Cash-flush Versartis swings for an $80M IPO to advance its orphan drug


0 No comments